Impact of antibiotics on the efficacy of immune checkpoint inhibitors in the treatment of primary liver cancer
Impact of antibiotics on the efficacy of immune checkpoint inhibitors in the treatment of primary liver cancer
复制标题
DOI：
10.1016/j.livres.2022.05.004
复制
发表时间：
2022-09-01
期刊：
影响因子：
--
通讯作者：
Xiao, Lu-Shan
中科院分区：
文献类型：
--
作者：
Wang, Jia-Ren;Li, Rui-Ning;Xiao, Lu-Shan
背景与目的：免疫检查点抑制剂（Immune checkpoint inhibitors，ICI）广泛应用于肝癌的治疗。但是，与其他药物的相互作用可能会改变ICI的疗效。很少有研究调查抗生素（ATB）对免疫治疗的疗效和接受免疫治疗的原发性肝癌患者的生存率的影响。本研究旨在探讨ATB对原发性肝癌患者免疫治疗疗效的影响。方法：共纳入2018年6月至2020年10月接受ICI治疗的215例原发性肝癌患者进行回顾性分析。比较免疫治疗前后30 d内接受和未接受ATB治疗的患者的无进展生存期（PFS）、疾病控制率（DCR）和总生存期（OS）。单因素和多因素分析显示使用ATB与PFS、DCR和OS无关。结论：原发性肝癌患者免疫治疗前后30 d内使用ATB对PFS、DCR和OS无不良影响。COPY; 2022中山大学附属第三医院。Elsevier B的出版服务。V.代表科爱传播有限公司，这是一个在CC BY-NC-ND许可证下的开放获取文章（http：//creativecommons.org/licenses/by-nc-nd/4.0/）。
Background and aim: Immune checkpoint inhibitors (ICIs) are widely used in the treatment of liver cancer. However, the interaction with other drugs may change the efficacy of ICIs. Few studies investi-gated the effects of antibiotics (ATBs) on the efficacy of immunotherapy and the survival of patients with primary liver cancer receiving immunotherapy. This study aimed to explore the impact of ATBs on the efficacy of immunotherapy in patients with primary liver cancer. Methods: In total, 215 patients with primary liver cancer who received ICIs from June 2018 to October 2020 were included for retrospective analysis. The progression-free survival (PFS), disease control rate (DCR), and overall survival (OS) were compared between patients treated with and without ATBs within 30 days before and after immunotherapy.Results: No significant differences in PFS (P = 0.376) and OS (P = 0.121) were found between patients treated with and without ATBs. Univariate and multivariate analyses showed that using ATBs was not associated with PFS, DCR, and OS.Conclusion: The use of ATBs within 30 days before and after immunotherapy in patients with primary liver cancer had no adverse effects on PFS, DCR, and OS.& COPY; 2022 The Third Affiliated Hospital of Sun Yat-sen University. Publishing services by Elsevier B. V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).